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Abstract
Background: Coronary artery calcification (CAC) is associated with cardiovascular mortality in end-stage renal
disease (ESRD) patients. The present study aimed to identify modifiable risk factors for CAC progression in
peritoneal dialysis (PD) patients.
Methods: Adult patients who received regular PD for more than 6 months and underwent a series of coronary
artery calcification score (CaCS) measurements by multislice spiral computed tomography (MSCT) with an interval
of≥ 6 months were included in this observational cohort study. The demographic characteristics and clinical data,
including laboratory data and adequacy of PD, were collected. Curve estimation was used to fit the straight line
and obtain the slope. Binary logistic regression was performed to identify the independent risk factors for CAC
progression in the PD patients, and multivariate linear regression was conducted to identify factors associated with
hyperphosphatemia.
Results: A total of 207 adult patients on PD (116 men, 56.0 %) with a mean age of 59.8 ± 15.9 years were recruited to
this study, and 157 of them (75.8 %) received three or more CaCS assessments. The patients were divided into a slow
group (n = 137) and a rapid group (n = 70) according to the linear regression slope or the average speed of
development. The follow-up time was 33.0 ± 18.8 months. Multivariate logistic regression revealed that age and serum
phosphate level were independent risk factors for CAC progression after adjustments. Multivariate linear regression
revealed that hyperphosphatemia was associated with elevations in the transferrin and serum albumin levels and
normalized protein catabolic rate (nPCR) and reductions in the hemoglobin level, residual Ccr, and PD Ccr.
Conclusions: Hyperphosphatemia is an independent risk factor for CAC progression, and the serum phosphate level
may be associated with protein intake and PD adequacy. These results provide important information for the clinical
management of ESRD patients.
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Background
Cardiovascular disease (CVD) is the leading cause of
death in patients on peritoneal dialysis (PD), and it is
more frequent in these patients than in the general
population. In addition, cardiovascular mortality is up to
100-fold higher in these patients than in the general age-
matched population, especially in younger patients [1,
2]. Although traditional risk factors for CVD in the gen-
eral population, including hypertension, diabetes melli-
tus and hyperlipidemia, are also important for PD
patients, other factors specific to end-stage renal disease
(ESRD) and/or PD also play important roles [3, 4]. The
presence, extent and progression of vascular calcification
are strongly associated with CVD and all-cause mortality
in ESRD patients [5–8]. Assessment of the coronary ar-
tery calcification score (CaCS) by computerized tomog-
raphy [9], a noninvasive imaging technique, has been
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suggested for evaluation of vascular calcification and has
been demonstrated to have a notable predictive value for
CVD.
Although coronary artery calcification (CAC) is an inde-
pendent prognostic predictor for ESRD patients [5–8], the
risk factors associated with CAC progression remain un-
certain. In the general population, traditional factors, such
as diabetes, hypertension and dyslipidemia, have been pro-
posed to contribute to its progression. In contrast with the
general population, ESRD patients are characterized by
complex complications, such as hypertension, mineral
metabolism disorder, micro-inflammation and a poor nu-
tritional state. Age, hypercalcemia, hyperphosphatemia,
PD duration, hyperlipidemia and inflammation are associ-
ated with CAC progression [8, 10–14].
Hyperphosphatemia is common in ESRD patients on
PD. Together with dysregulated calcium, parathyroid
hormone and vitamin D levels, hyperphosphatemia
contributes to mineral and bone diseases [15–17]. Epi-
demiological studies have suggested that hyperpho-
sphatemia is associated with increased cardiovascular
events and all-cause mortality and that a decrease in
the serum phosphate level is linked to improved sur-
vival [18–21]. Upon exposure to high phosphate
levels, bone-like cells form in arteries, resulting in ex-
tensive calcification [22, 23]. Hyperphosphatemia has
been associated with increases in vessel wall thickness
and arterial stiffness [24]. However, the association be-
tween hyperphosphatemia and CAC progression re-
mains controversial in ESRD patients on PD [10, 11,
13, 14, 25].
The aim of this study was to examine the potential risk
factors for CAC progression in ESRD patients on PD. In
addition, we sought to determine whether hyperpho-
sphatemia is an independent risk factor for CAC pro-




Adult patients on PD treated at Huashan Hospital Fudan
University in China from January 2007 to October 2012
were included in this observational cohort study. Pa-
tients who received regular PD for more than 6 months
and underwent CaCS measurements at least twice with
an interval of ≥ 6 months were analyzed. Patients were
excluded if they had acute infection, unstable CVD or
were clinically unstable, with a life expectancy of shorter
than 6 months. Patients whose active disease was stable
for over 2 months were eligible for this study. This study
was approved by the ethics committee of Huashan Hos-
pital at Fudan University. All of the patients gave written
informed consent.
Coronary artery calcification score
CAC was assessed by multislice spiral computed tomog-
raphy (MSCT) and recorded as the Agatston score
(CaCS). In this method, the heart was scanned over a
period of 20 to 30 s, with a distance of 3 mm between
each slice. The software built into this equipment detected
calcified lesions with a density of at least 130 Hounsfield
units and a minimal area of 0.5 mm2. The acquisition time
for this method was 125 milliseconds. For imaging recon-
struction, this method used data obtained during the dia-
stolic phase of the cardiac cycle. The total radiation dose
throughout the entire procedure was 1.25 millisieverts
(mSV). Calculations of the total CaCS were based on for-
mulas that included measurements of the total volume,
area and mean and maximum densities of the calcified le-
sions. Individual CaCS were calculated for the left main
coronary artery, descending branch of the left coronary ar-
tery, circumflex branch of the left coronary artery and
right coronary artery. Then, the scores were summed to
calculate the total coronary CaCS. The final score is
expressed in modified Agatston units.
Evaluation of coronary artery calcification progression
All patients with a CaCS of 0 during follow-up were
placed into the slow progression group. For the other
patients, the dependent variable, Yn = the square root of
CaCSn (SQRCaCSn), and the independent variable, Tn =
Dn - D1 (Tn represents the time interval between the n
th
and 1st CaCS assessment), were calculated. If Yn = f(Tn)
fitted the linear relationship for each patient, then V =
f(Tn)/Tn was calculated. If not, the average speed of de-
velopment represented by the geometric average,ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CaCn=CaCS1t
p
; was calculated. The patients with a V ≥
0.3 (median) or a geometric average ≥ 1.03 (median)
were placed into the rapid CAC progression group, and
those with a V < 0.3 or a geometric average < 1.03 were
classified as the slow group.
Laboratory data
Demographic characteristics (age, gender, height, weight
and smoking status) and comorbidities (diabetes melli-
tus, hypertension and CVD) were recorded at baseline.
Laboratory measurements, including calcium-phosphate
metabolism (the serum phosphate level, adjusted cal-
cium level, as calculated by [measured calcium + (4 – al-
bumin g/dL) × 0.8], and intact parathyroid hormone
[iPTH] level), lipid (cholesterol, triglycerides, low-density
lipoprotein, high-density lipoprotein [HDL] and lipopro-
tein a), inflammation marker (high-sensitivity C-reactive
protein and fibrinogen), hemoglobin, albumin, transfer-
rin, serum iron and pro-brain natriuretic peptide (pro-
BNP) levels, were collected every 3 months. The average
values of these indexes were calculated between CaCS
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measurements. PD adequacy was evaluated every
6 months using Baxter PD Adequest 2.0 software (Baxter
Healthcare Corporation, Deerfield, IL, USA), and the av-
erages of these parameters, including the total Kt/V, re-
sidual Kt/V, total clearance of creatinine (Ccr), residual
Ccr and normalized protein catabolic rate (nPCR), were
obtained. In addition, the clearance of phosphate (Cp)
and calcium (Cca) by the dialysate, adjusted for the body
surface area (BSA), the peritoneal permeability for phos-
phate (D4/P phosphate = the phosphate concentration in
the dialysate at the 4th hour / the plasma phosphate con-
centration) and the D/P phosphate or calcium (the mean
phosphate or calcium concentration in the dialysate /
the plasma phosphate or calcium concentration), were
also obtained.
Statistical analysis
Statistical analysis of the data was performed using SPSS
software, version 17.0. Continuous variables are
expressed as the mean ± SD or as the median and quar-
tile range, and categorical variables are expressed as per-
centages. Groups were compared using the independent
samples t-test or Mann–Whitney U test for continuous
variables and Pearson’s chi-square test or Fisher’s exact
test for categorical variables. Curve estimation was per-
formed for linear regression analysis. Binary logistic re-
gression was used to identify the independent risk
factors for CAC in the PD patients. Covariates that were
considered risk factors for the endpoints in univariate
analysis were used for adjustments. The odds ratios
(ORs) for the endpoints are expressed per 10-year age
interval, 100-unit increase in the baseline CaCS, and
0.1 g/dL increase in the albumin level. Univariate linear
regression was performed to identify the factors poten-
tially related to hyperphosphatemia. Multivariate linear
regression was conducted to verify the risk factors and
covariates associated with hyperphosphatemia identified
in univariate analysis and for adjustments. The associa-
tions between hyperphosphatemia and other factors
were expressed by unstandardized and standardized co-
efficients. All of the statistical tests were 2-sided, and the
differences were considered statistically significant at a
P-value of < 0.05.
Results
Patients’ characteristics
A total of 207 adult patients on PD (116 men, 56.0 %)
with a mean age of 59.8 ± 15.9 years were recruited for
this study. The follow-up time was 33.0 ± 18.8 months.
A total of 70 patients started PD before initiation of the
study (from 0.5 - 9 years prior). The average duration of
PD therapy for all of the patients at baseline was 1.08
(−0.26 - 7.10) months, and there were no significant dif-
ferences between the groups. Sixty-eight patients were
followed for less than 2 years, 89 for more than 2 years
but less than 4 years, and 50 for more than 4 years
(Fig. 1). One hundred and fifty-seven (75.8 %) patients
received ≥ 3 CaCS assessments, 116 (56 %) received ≥ 4
and 69 (33.3 %) had ≥ 5. In addition, 137 (66.2 %) pa-
tients received baseline CaCS examination from 1 month
before PD to 6 months after PD. The basic CaCS was 0
for 84 (40.6 %) patients, 1 to 100 for 53 (25.6 %) pa-
tients, and ≥ 100 for 70 (33.8 %) patients.
More than 90 % of the patients in our study received
continuous ambulatory peritoneal dialysis (CAPD), while
others received daytime ambulatory peritoneal dialysis
(DAPD). The peritoneal dialysates used for all patients
were Dianeal PD4 (1.25 mmol/L calcium, 2 L) and Dia-
neal PD2 (1.75 mmol/L calcium, 2 L) from Baxter
Healthcare Corporation. Approximately 93 % of the pa-
tients received 3 changes (62 %) or 4 changes (31 %) of
dialysate, and the long and short dwelling times were
12 h and 4 to 6 h, respectively. No icodextrin was used
at our center because it is not available in China. There
were no significant differences in the use of CAPD or
Dianeal PD4/PD2 between the rapid and slow groups.
Eight patients had a history of cardiovascular events
(CVEs) at baseline, and there were no significant differ-
ences between the groups (1/70 vs. 7/137, p = 0.195).
During the follow-up period, 57 patients died and 54 ex-
perienced CVEs. Among the patients who died, 25 died
of a CVE and 14 died of infection. A total of 25 patients
died in the rapid group (70 patients), and 32 died in the
slow group (137 patients).
Among the patients, 61 (29.5 %) had a history of dia-
betes at the beginning of the study, and 78 (37.7 %) had
Fig. 1 The relationship between the interval and number of patients
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a history of smoking. Thirty-nine (18.8 %) patients had a
serum phosphate level of > 5.5 mg/dL, and 117 (56.5 %)
had a level of > 4.5 mg/dL. Among these patients, 133
(64.3 %) received calcium carbonate treatment (78/137
vs. 55/70; p = 0.002), and 143 (69.1 %) received calcitriol
treatment. Forty-three (20.8 %) patients had a serum
cholesterol level of >200 mg/dL, and 138 (66.7 %) re-
ceived lipid-lowering drugs. All of the treatments were
strictly administered according to the K/DOQI or
KDIGO guidelines and were not influenced by this
study. The mean hemoglobin level was 103.6 ± 13.1 g/L,
and the mean nPCR was 0.87 ± 0.16. The median serum
albumin level was 3.47 g/dL. In total, 116 (56.0 %) pa-
tients had an average residual renal Ccr of > 20 L/week,
97 (46.9 %) had an average total Ccr of > 65 L/week, and
180 (87.0 %) had a total Ccr of > 50 L/week. The mean
D4/P phosphate was 0.53 ± 0.12, which was strongly as-
sociated with the D4/P creatinine, and the D/P phos-
phate was 0.59 ± 0.16.
Hyperphosphatemia is an independent risk factor for
CaCS progression
Sixty-three patients with a CaCS of 0 were placed into
the slow group, with a mean follow-up time of 32.7 ±
19.1 months, which was similar to that of the other 144
patients (33.1 ± 18.7 months; p = 0.898). Among the 144
patients, the progression of calcification fitted the linear
relationship in 63, and it did not in 81. The 31 patients
with a V < 0.3 and the 43 patients with a geometric aver-
age < 1.03 were also placed into the slow group. The
remaining patients (n = 70) were classified as the rapid
group. Univariate analysis revealed that the patients with
rapid progression were older, had a higher baseline CaCS
and had a higher absolute change in the calcification
score at the end of the observation period versus the
baseline (absolute CaCS) compared with the slow group.
Further, the patients with rapid progression had a higher
body mass index (BMI) and serum phosphate, serum
creatinine and lipoprotein a levels but lower HDL and
hemoglobin levels. With regard to inflammation, the pa-
tients with rapid progression had a higher hs-CRP level.
With regard to PD adequacy, the patients with slow pro-
gression had elevations in total Ccr and Kt/V, residual
renal function and D/P phosphate. Unexpectedly, the pa-
tients with slow progression had a higher D/P phos-
phate, but no significant differences were found in the
excretion of calcium and phosphate in the dialysate
between the slow and rapid groups. No significant cor-
relation in gender, the cause of ESRD, the iPTH, choles-
terol, or triglyceride level, nPCR, PD-Ccr or Kt/V was
observed between the slow and rapid progression groups
(Table 1). Multivariate analysis revealed that age (p =
0.023) and serum phosphate level (p = 0.031) were inde-
pendent risk factors for CAC progression after adjusting
for gender, basic CaCS, lipoprotein a, HDL, hemoglobin,
serum creatinine, and hs-CRP levels, total Ccr, residual
Ccr and D/P phosphate (Table 2).
In addition, we analyzed the serum phosphate levels in
the 63 patients with a CaCS of 0 throughout the study,
and compared them with those of the slow progressors
(those with a CaCS of 0 throughout the study were ex-
cluded) and rapid progressors [26]. In univariate ana-
lysis, the serum phosphate level in the rapid progressors
(5.0 ± 0.88 mg/dL) was significantly higher than that of
the slow progressors (4.37 ± 0.86 mg/dL, p < 0.001), con-
sistent with our previous results. However, the serum
phosphate level in the patients who did not experience
CAC during study (4.84 ± 1.06 mg/dL) did not differ
compared with that in the rapid progressors (p = 0.36)
and was significantly higher than that in the slow pro-
gressors. Multivariate analysis revealed that serum phos-
phate level was an independent risk factor for CAC
progression after adjusting for age, gender, basic CaCS,
total Ccr, hemoglobin level, and BMI (p = 0.048). These
findings suggest that the serum phosphate level is not a
risk factor contributing to the initiation of vascular
calcification.
The risk factors for hyperphosphatemia
Linear regression was performed to analyze associations
between the average serum phosphate level and other
factors. Univariate analysis showed that nutritional
markers (serum transferrin, BUN, and albumin levels
and nPCR), calcium phosphate metabolism (the iPTH
level, Cp, Cca and D/P phosphate) and the pro-BNP
level were positively associated with the serum phos-
phate level. In contrast, age, the hemoglobin level and
PD adequacy (total Ccr and Kt/V, residual Ccr and Kt/
V) were inversely associated with this level, and the dia-
lysis Ccr and Kt/V, BMI, and adjusted calcium, hs-CRP
and lipid levels were not significantly associated with it
(Table 3). Multivariate analysis revealed that the patients
with hyperphosphatemia were younger (p = 0.003). Other
factors found to be independently associated with hyper-
phosphatemia were elevations in the transferrin (p
= 0.007) and serum albumin levels (p = 0.049) and nPCR
(p < 0.001) and decreases in the hemoglobin level (p =
0.015), residual Ccr (p < 0.001), and PD Ccr (p <
0.001) (Table 4).
Discussion
The aim of this study was to determine the risk factors
for and whether hyperphosphatemia was independently
associated with CAC progression. We found that age
and hyperphosphatemia were independent risk factors
for CAC progression after adjusting for basic CaCS, lipid
levels, inflammation, D/P phosphate and PD adequacy.
The serum phosphate level was positively associated
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Table 1 Clinical characteristics of the peritoneal dialysis patients
Total (n = 207) Slow Group (n = 137) Rapid Group (n = 70) P-value
Follow-up time (months) 33.0 ± 18.8 33.9 ± 19.7 31.2 ± 16.7 0.299
Age (years) 59.8 ± 15.9 58.0 ± 17.0 63.4 ± 13.1 0.012
BMI (kg/m2) 23.56 ± 3.72 22.87 ± 3.69 24.90 ± 3.40 <0.001
Gender (male) 56.0 % 52.60 % 62.90 % 0.184
Cause of ESRD 0.311
Glomerulonephritis 59.9 % 61.3 % 57.1 %
Diabetes mellitus 29.5 % 24.8 % 38.6 %
Polycystic kidney 2.4 % 2.9 % 1.4 %
Hypertension 2.4 % 3.6 % 0 %
Others 5.8 % 7.3 % 2.9 %
Smoking 37.7 % 34.30 % 44.30 % 0.175
Diabetes mellitus 29.5 % 24.80 % 38.60 % 0.053
CVD before PD 3.9 % 5.1 % 1.4 % 0.195
PD duration before CAC (months) 1.08 (−0.26-7.10) 1.08 (−0.31-6.39) 1.18 (−0.16-10.87) 0.380
Baseline CaCS 13.8 (0–239.0) 0 (0–175.2) 71.4 (1.5-304.0) 0.001
Absolute CaCS 61.7 (0–370.6) 0 (0–115.5) 381.8 (103.0-907.4) <0.001
nPCR (g/kg*d) 0.87 ± 0.16 0.88 ± 0.16 0.84 ± 0.14 0.107
Total protein (g/dL) 6.55 ± 0.53 6.56 ± 0.51 6.55 ± 0.58 0.931
Albumin (g/dL) 3.47 (3.25-3.70) 3.50 (3.28-3.75) 3.42 (3.22-3.59) 0.052
Cholesterol (mg/dL) 173 (157–197) 172 (154–197) 173 (159–197) 0.918
Triglycerides (mg/dL) 155 (114–209) 151 (113–210) 163 (122–209) 0.386
LDL (mg/dL) 95.0 ± 23.2 94.0 ± 23.7 96.8 ± 22.4 0.424
Lipoprotein a (mg/dL) 198 (125–324) 182 (110–319) 258 (168–325) 0.01
HDL (mg/dL) 37.1 (32.1-43.3) 38.3 (32.7-46.4) 36.5 (32.0-40.3) 0.03
Serum creatinine (mg/dL) 9.09 ± 3.26 8.68 ± 3.22 9.90 ± 3.22 0.011
Pro-BNP (pg/mL) 5094 ± 6592 4542 ± 5625 6188 ± 8121 0.106
Adjusted total Ccr (L/W) 63.6 (54.3-76.1) 56.6 (67.0-83.1) 58.0 (51.1-67.2) <0.001
Adjusted PD Ccr (L/W) 40.0 ± 8.9 39.9 ± 8.9 40.2 ± 9.0 0.785
Adjusted residual Ccr (L/W) 29.0 ± 25.3 32.9 ± 27.1 21.2 ± 19.1 <0.001
Total Kt/V 2.03 ± 0.40 2.11 ± 0.42 1.89 ± 0.32 <0.001
PD Kt/V 1.48 ± 0.37 1.47 ± 0.38 1.49 ± 0.35 0.772
Residual Kt/V 0.45 (0.16-0.79) 0.55 (0.22-0.86) 0.32 (0.13-0.56) 0.002
D/P phosphate 0.59 ± 0.16 0.61 ± 0.18 0.55 ± 0.11 0.007
D/P calcium 0.58 (0.50-0.62) 0.58 (0.50-0.62) 0.58 (0.48-0.62) 0.58
Cp (mmol/d/1.732) 4.58 ± 1.77 4.39 ± 1.78 4.93 ± 1.71 0.069
Cca (mmol/d/1.732) 0.64 ± 0.61 0.59 ± 0.58 0.74 ± 0.66 0.132
D4/P phosphate 0.53 ± 0.12 0.54 ± 0.12 0.51 ± 0.13 0.161
iPTH (ng/dL) 297 (195–416) 286 (186–420) 323 (212–412) 0.329
Phosphorus (mg/dL) 4.72 ± 0.97 4.59 ± 0.98 4.99 ± 0.88 0.005
Adjusted calcium (mg/dL) 9.13 ± 0.67 9.15 ± 0.60 9.09 ± 0.79 0.51
Hemoglobin (g/L) 103.6 ± 13.1 105.1 ± 13.5 100.5 ± 11.8 0.015
hs-CRP (mg/dL) 0.19 (0.09-0.34) 0.15 (0.07-0.32) 0.24 (0.17-0.41) 0.001
CAPD 91.2 % 93.5 % 88.3 % 0.092
Calcium carbonate use 64.3 % 56.90 % 78.60 % 0.002
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with nutritional markers, including the transferrin and
serum albumin levels and nPCR, but negatively associ-
ated with age, the hemoglobin level and PD adequacy,
including the peritoneal and residual renal Ccr. These
results suggest that hyperphosphatemia accelerates the
progression of vascular calcification, and treatments that
lower the serum phosphate level, including restriction of
phosphate intake and protection of residual renal func-
tion, may be beneficial for ESRD patients receiving PD.
In addition, our study showed that diabetes mellitus
had a trend of a higher prevalence (p = 0.053) in the
rapid progression group, as determined by univariate
analysis. This finding may be associated with the stimu-
lation of glycoxidation and hypoxia during arterial
hyperglycemia. Further studies are required to identify
the metabolic factors that are related to diabetes and
contribute to aortic calcification in diabetic PD patients
[27]. Rroji M’s study has shown that residual renal func-
tion in PD patients contributes significantly to the main-
tenance of phosphate balance and may explain the lower
prevalence of valve calcification in PD patients com-
pared with HD patients. Residual renal function not only
allows for small solute clearance but also plays import-
ant roles in maintaining the fluid balance and phosphate
control and removing middle molecule uremic toxins
[28, 29]. In our study, dialysis adequacy was associated
with CAC progression, as shown by univariate analysis,
highlighting the importance of RRF in the control of
vascular calcification.
Vascular calcification is significantly associated with
the prognosis of ESRD patients [5–8]; therefore, some
studies have focused on the risk factors for vascular cal-
cification progression. In Noordzij’s study [14], 237 pa-
tients on PD/HD were enrolled, and chest X-ray was
performed to evaluate the progression of aortic calcifica-
tion during follow-up (mean of 2.3 years). They found
that aortic calcification progressed in almost one-third
of the patients. In addition, age, hypercalcemia and
hyperparathyroidism were associated with an increased
risk of progression, while hyperphosphatemia was not
associated with progression. Another study on aortic cal-
cification included 184 PD/HD patients and found that
dialysis duration and the basic calcification score were
associated with progression [11]. Studies on CAC have
reported that the levels of cholesterol, LDL and inflam-
mation markers, such as CRP, are positively associated,
but that serum albumin is inversely associated, with pro-
gression [8, 12, 13, 30]. A few studies have shown that
BMI and hyperphosphatemia are independent risk fac-
tors for CAC progression [25]. Hence, the risk factors
for vascular calcification remain unclear. In our study,
age, basic CaCS, BMI, phosphate, HDL, lipoprotein a,
hemoglobin, and hs-CRP levels, D/P phosphate and dia-
lysis adequacy were associated with CAC progression, as
shown by univariate analysis. However, the results of
multivariate analysis indicated that only age and serum
phosphate level were independent risk factors.
Chronic hyperphosphatemia in patients undergoing
dialysis is associated with elevations in cardiovascular
morbidity and mortality [18–21]. Since the late 1980s,
the focus of nephrologists has drastically shifted from
bone damage and extravascular calcification of soft tis-
sues to cardiovascular damage related to hyperphospha-
temia. The mechanisms of this damage are thought to
be linked to the ability of phosphate to enhance vascular
calcification [31]. Extracellular phosphate promotes the
mineralization of vascular smooth muscle cells in both
dosage- and time-dependent manners by inducing osteo-
blastic differentiation factors [32]. Whether hyperpho-
sphatemia is associated with the progression of vascular
calcification remains controversial in clinical studies.
Noordzij’s study [14] has revealed that hypercalcemia
and hyperparathyroidism are associated with an in-
creased risk of progression but that hyperphosphatemia
is not. Stompor’s study [25] has shown that hyperpho-
sphatemia is associated with CAC progression by univar-
iate analysis but that it is not an independent risk factor.
Other studies have also shown that hyperphosphatemia
Table 1 Clinical characteristics of the peritoneal dialysis patients (Continued)
Calcitriol use 69.1 % 67.90 % 71.40 % 0.637
Lipid-lowering drug use 66.7 % 62.80 % 74.30 % 0.119
Table 2 Multivariate analyses of the selected possible risk
factors for CaCS progression in PD patients
OR P
Age (per 10 years) 1.503 (1.059-2.133) 0.023
Gender 2.021 (0.778-5.245) 0.148
BMI (kg/m2) 1.134 (0.988-1.302) 0.073
Baseline CaCS (per 100) 1.004 (0.955-1.056) 0.873
Total Ccr (L/W) 1.005 (0.935-1.080) 0.898
Residual Ccr (L/W) 0.983 (0.930-1.039) 0.539
D/P phosphate 0.142 (0.007-3.051) 0.213
Phosphorus (mg/dL) 2.043 (1.068-3.910) 0.031
Hemoglobin (g/dL) 0.983 (0.950-1.018) 0.337
Lipoprotein a (mg/dL) 1.001 (1.000-1.003) 0.138
HDL (mg/dL) 0.986 (0.939-1.035) 0.569
hs-CRP (mg/dL) 1.663 (0.377-7.338) 0.502
Serum creatinine (mg/dL) 0.980 (0.784-1.224) 0.856
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is not a risk factor for CAC progression [8, 10–12, 30].
In contrast with the above studies, we found that hyper-
phosphatemia was an independent risk factor for CAC
progression after adjusting for age, gender, BMI, baseline
CaCS, HDL, lipoprotein a, hemoglobin, serum creatin-
ine, and hs-CRP levels, total Ccr, residual Ccr and D/P
phosphate. This disparity among results may be attrib-
uted to the following factors: 1. the serum phosphate
level was an average level measured during the follow-
up period in our study, and thus it better represented
the actual level compared with the use of only the base-
line level. 2. The sample size of our study was larger and
the follow-up time was longer than those in the previous
studies. 3. The patients recruited to our study received a
series of CaCS assessments, which was superior to the
evaluation of calcification by two CaCS measurements.
4. The heterogeneity of our study population was rela-
tively small because all of the patients were stable PD
patients, and approximately two-thirds of them were re-
cruited to our cohort at the beginning of PD treatment.
Our univariate analysis showed that calcium carbonate
use was associated with CAC progression (78/137 vs.
55/70; p = 0.002). Because only patients with hyperpho-
sphatemia were prescribed calcium carbonate in our co-
hort, we considered them as two dependent variables.
Therefore we did not include calcium carbonate in
multivariate analysis. However, we analyzed the correl-
ation of the serum phosphate level and CaCS progres-
sion by partial correlation analysis, adjusting for the
calcium carbonate level, age, BMI, sex, renal residual
Ccr and basic CaCS. We found that the serum phos-
phate level was associated with CaCS progression.
Therefore, our results suggest the serum phosphate level
is an independent risk factor for CaCS progression, but
they do not exclude the possible association of the cal-
cium carbonate level with the CaCS.
If hyperphosphatemia is independently associated with
the progression of vascular calcification, then control of
the serum phosphate level may be beneficial for improv-
ing the prognosis of ESRD patients. Therefore, studies
on the risk factors for hyperphosphatemia are useful for
achieving serum phosphate control. In a multi-center
observational study of phosphate control in PD patients
[33], the serum phosphate level was found to be
Table 3 Univariate analysis for the selected possible predictors






Age (per 10 years) −0.247 ± 0.039 −0.407 <0.001
Gender 0.157 ± 0.135 0.081 0.247
Baseline CaCS
(per 100 ng/L)
−0.008 ± 0.007 −0.086 0.22
BMI (kg/m2) 0.019 ± 0.018 0.072 0.304
Transferrin (g/L) 0.123 ± 0.043 0.195 0.005
BUN (mmol/L) 0.015 ± 0.005 0.231 0.001
Albumin (g/dL) 0.461 ± 0.117 0.265 <0.001
nPCR (g/kg · d) 1.710 ± 0.418 0.275 <0.001
Hemoglobin (g/L) −0.027 ± 0.005 −0.359 <0.001
CO2CP (mmol/L) −0.090 ± 0.025 −0.245 <0.001
Adjusted calcium
(mg/dL)
−0.138 ± 0.101 −0.095 0.173
iPTH (per 100 ng/L) 0.122 ± 0.031 0.272 <0.001
hs-CRP (mg/dL) −0.001 ± 0.003 −0.019 0.793
Pro-BNP (ng/mL) 0.033 ± 0.010 0.245 0.001
Cholesterol
(per 100 mg/dL)
0.097 ± 0.076 0.089 0.2
Triglycerides
(per 100 mg/dL)
−0.022 ± 0.071 −0.022 0.755
LDL (per 100 mg/
dL)
−0.147 ± 0.290 −0.035 0.614
HDL (per 100 mg/
dL)
−0.442 ± 0.289 −0.106 0.128
Lipoprotein a
(per 100 mg/dL)
0.006 ± 0.003 0.015 0.838
Total Ccr (L/W) −0.017 ± 0.003 −0.372 <0.001
PD Ccr (L/W) −0.013 ± 0.008 −0.121 0.082
Residual Ccr (L/W) −0.010 ± 0.003 −0.266 <0.001
Total K/tv −0.985 ± 0.152 −0.412 <0.001
PD K/tv −0.317 ± 0.181 −0.122 0.081
Residual K/tv −0.465 ± 0.131 −0.241 <0.001
Cp (mmol/d/1.732) 0.297 ± 0.033 0.581 <0.001
Cca (mmol/d/1.732) 0.313 ± 0.117 0.21 0.008
D4/P phosphate −1.265 ± 0.586 −0.174 0.033
D/P phosphate 0.083 ± 0.462 0.015 0.858
D/P calcium −0.105 ± 0.099 −0.086 0.292
Table 4 Multivariate analysis of selected factors associated with







Age (per 10 years) −0.122 ± 0.040 −0.211 0.003
Gender 0.051 ± 0.121 0.028 0.671
Transferrin (g/L) 0.098 ± 0.036 0.162 0.007
Albumin (g/dL) 0.188 ± 0.095 0.128 0.049
nPCR (g/kg/d) 1.560 ± 0.416 0.265 <0.001
Hemoglobin (g/L) −0.011 ± 0.005 −0.165 0.015
iPTH (per 100 ng/
L)
0.049 ± 0.026 0.120 0.061
Residual Ccr (L/W) −0.021 ± 0.003 −0.590 <0.001
PD Ccr (L/W) −0.037 ± 0.009 −0.355 <0.001
D4/P phosphate −0.858 ± 0.462 −0.119 0.065
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positively correlated with the serum albumin and iPTH
levels and negatively correlated with age. Another study
[28] showed that hyperphosphatemia was positively cor-
related with BMI, the iPTH level and nPNA (normalized
protein equivalent of nitrogen appearance) and inversely
correlated with PD Ccr/Kt/v and residual GFR. Similar
to these studies, we found that hyperphosphatemia was
positively associated with nPCR and the albumin and
transferrin levels and negatively associated with age and
PD adequacy. These findings may suggest that the serum
phosphate level is mainly determined by dietary phos-
phate intake and PD adequacy. Therefore, the restriction
of phosphate intake and increase in PD adequacy may
be useful for slowing the progression of vascular calcifi-
cation. In addition, the level of serum phosphate was
negatively associated with that of hemoglobin, a finding
that may be attributed to the increased levels of poly-
amines caused by hyperphosphatemia, which can inhibit
erythropoiesis [34, 35].
There are some limitations to our study. First, this re-
port was an observational, single-center and relatively
small study. Our results only describe hyperphosphate-
mia as an independent risk factor for CAC progression,
and we only analyzed factors related to the serum phos-
phate level. We did not examine whether the control of
serum phosphate could slow CAC progression. Second,
the follow-up times for the patients in this study varied
from 6 to 87 months, and approximately 15 % of them
were followed up for less than 12 months. CAC progres-
sion was not linear in a portion of the patients; thus, we
calculated the velocity according to the average speed of
development represented by the geometric average,
which may have introduced error.
Conclusions
In conclusion, our results indicate that hyperphosphate-
mia is an independent risk factor for CAC progression,
that high BMI has a trend of increased prevalence in PD
patients and that the serum phosphate level is positively
associated with nutritional markers and PD adequacy,
indicating that a high daily phosphate intake and PD in-
adequacy may accelerate CAC progression. Control of
serum phosphate might slow the progression of vascular
calcification and improve the prognosis of PD patients.
However, these results require further examination by
interventional trials.
Strengths
First, the lab data comprised the average levels measured
during the follow-up period, which better represented
the actual levels. Second, the sample size of our study
was larger, and the follow-up time was longer. Third, the
patients recruited for our study received a series of CaCS
assessments, which is superior to the evaluation of calci-
fication by two CaCS measurements.
Limitations
First, this report was an observational, single-center and
relatively small study. We did not examine whether the
control of serum phosphate could slow CAC progres-
sion. Second, the follow-up times of these patients varied
from 6 months to 87 months. Linear regression and geo-
metric averages were used to evaluated CAC progres-
sion, which may have introduced errors.
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